Mizuho, Alkermes
Alibaba price target raised to $113 from $92 at Mizuho
Mizuho analyst James Lee raised the firm’s price target on Alibaba (BABA) to $113 from $92 and keeps an Outperform rating on the shares. While stimulus policies are driving enthusiasm in China, Asia internet fundamentals remain soft and uncertain,
BofA raised the firm’s price target on Alkermes (ALKS) to $31 from $28 and keeps a Neutral rating on the shares, citing a higher multiple given the recent move in biotech peer comps for the ...
Stifel has upgraded Alkermes (NASDAQ:ALKS) to buy from hold, citing increased confidence in the company’s narcolepsy drug ...
Fintel on MSN8d
Stifel Upgrades Alkermes (ALKS)Fintel reports that on November 5, 2024, Stifel upgraded their outlook for Alkermes (NasdaqGS:ALKS) from Hold to Buy. Analyst ...
Alkermes is a biopharmaceutical company primarily involved in developing treatments for central nervous system disorders. Its current lineup includes schizophrenia treatment Aristada ...
Alkermes (NASDAQ:ALKS) is gearing up to announce its quarterly earnings on Thursday, 2024-10-24. Here's a quick overview of what investors should know before the release. Analysts are estimating ...
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Alkermes (ALKS) reported $378.14 million in revenue for the quarter ended September 2024, representing a year-over-year decline of 0.7%. EPS of $0.73 for the same period compares to $0.64 a year ago ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback